Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Single nuclear RNA sequencing of Benign Prostate Hyperplasia tissue

ABSTRACT: Single nuclear RNA sequencing of Benign Prostate Hyperplasia tissue

PROVIDER: PRJEB75335 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ERR12954266_1.fastq.gz	Fastqsanger.gz
	ERR12954266_2.fastq.gz	Fastqsanger.gz
	ERR12954267_1.fastq.gz	Fastqsanger.gz
	ERR12954267_2.fastq.gz	Fastqsanger.gz
	ERR12954268_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 8

Similar Datasets

Single nuclear ATAC sequencing of Benign Prostate Hyperplasia tissue

Project description:Single nuclear ATAC sequencing of Benign Prostate Hyperplasia tissue

| PRJEB74995 | ENA

Serum proteomics in prostate cancer patients vs. healthy and benign prostate hyperplasia

Project description:The study aim was to identify novel serum markers of prostate cancer diagnosis compared to benign prostate hyperplasia and healthy controls

2016-10-04 | PXD004575 | Pride

Differential gene expression in canine prostate cancer vs benign prostate hyperplasia tissue.

Project description:Differential gene expression in canine prostate cancer vs benign prostate hyperplasia tissue.

| PRJNA1272546 | ENA

Differential gene expression in canine prostate cancer vs benign prostate hyperplasia tissue. [NanoString]

Project description:Differential gene expression in canine prostate cancer vs benign prostate hyperplasia tissue. [NanoString]

| PRJNA1272558 | ENA

Differential gene expression in canine prostate cancer vs benign prostate hyperplasia tissue.

Project description:Despite its low incidence, the aggressive nature and high metastatic potential of canine prostate cancer (PC) make it a serious problem in veterinary medicine. However, knowledge of the molecular mechanisms and regulatory networks underlying the development and progression of canine PC is still limited. We used RNAseq to identify diffentially expressed genes between PC (n=2) and benign prostate hyperplasia (BPH, n=3) samples. Based on these results, we chose 26 genes for validation on a larger patient cohorts. We used Nanosting nCounter technology for the comparative analysis of gene expression profiles in PC (n=14) and BPH (n=7) tissue samples. Finally the results for voltage-dependent calcium channel α2δ1 subunit were validated using Western blotting and immunohistochemistry.

2025-09-01 | GSE299084 | GEO

Differential gene expression in canine prostate cancer vs benign prostate hyperplasia tissue. [NanoString]

2025-09-01 | GSE299093 | GEO

Tissue Proteome Signatures Associated with Five Grades of Prostate Cancer and Benign Prostatic Hyperplasia

Project description:Prostate cancer (PCa) remains a prevalent and deadly disease. The histology-based Gleason score (GS) of PCa tissue biopsy is the most accurate predictor of disease aggressiveness and an important measure to guide decision-making with respect to treatment strategies and patient management. However, inherent variability associated with PCa tumour sampling and the subjective determination of the GS are still key challenges precluding accurate diagnostication and prognostication. Thus, novel molecular signatures are urgently needed to distinguish between indolent and aggressive forms of PCa for better patient management and outcomes. Herein, we have used label-free LC-MS/MS-based proteomics to profile the proteome of 50 PCa tissues spanning five GS-based PCa grades (n = 10 per group) relative to five tissues from individuals with benign prostatic hyperplasia (BPH). Over 2,000 proteins were consistently identified albeit at different levels between and within the patient groups, revealing biological processes associated with specific grades. Excitingly, a panel of 11 prostate-derived proteins including IGKV3D-20, RNASET2, TACC2, ANXA7, LMOD1, PRCP, GYG1, NDUFV1, H1FX, APOBEC3C, CTSZ displayed the potential to accurately stratify patients displaying low and high GS. This is the first study to characterise the prostate tissue proteome signatures of the five PCa grades relative to BPH. We report a panel of proteins that accurately can distinguish low and high GS PCa tissues. These promising proteins can be further explored as candidate biomarkers for PCa aggressiveness.

2019-10-09 | PXD013837 | Pride

Preclinical evaluation of waste-derived pomegranate extract (PWE) as potential preventing and therapeutic for benign prostatic hyperplasia

Project description:This dataset contains LC-MS/MS proteomics data from liver and prostate tissues of Rattus norvegicus. Rats were treated with testosterone to model benign prostatic hyperplasia (BPH) and subsequently with pomegranate waste extract (PWE) to assess its effect on the tissue proteome.

2026-02-12 | MSV000100818 | MassIVE

Illumina M450 profiling of human prostate cancer tissue and benign prostate tissue

Project description:Illumina M450 profiling was conducted on clinically-annotated human prostate cancer tissue and benign prostate tissue

2017-04-10 | GSE76938 | GEO

Combination of autoantibody signature with PSA level enables a highly accurate blood-based differentiation of prostate cancer patients from patients with benign prostatic hyperplasia

Project description:Although an increased level of the prostate-specific antigen can be an indication for prostate cancer, other reasons often lead to a high rate of false positive results. Therefore, an additional serological screening of autoantibodies in patients’ sera could improve the detection of prostate cancer. We performed protein macroarray screening with sera from 49 prostate cancer patients, 70 patients with benign prostatic hyperplasia and 28 healthy controls and compared the autoimmune response in those groups. We were able to distinguish prostate cancer patients from normal controls with an accuracy of 83.2%, patients with benign prostatic hyperplasia from normal controls with an accuracy of 86.0% and prostate cancer patients from patients with benign prostatic hyperplasia with an accuracy of 70.3%. Combining seroreactivity pattern with a PSA level of higher than 4.0 ng/ml this classification could be improved to an accuracy of 84.1%. For selected proteins we were able to confirm the differential expression by using Lluminex on 84 samples. We provide a minimally invasive serological method to reduce false positive results in detection of prostate cancer and according to PSA screening to distinguish men with prostate cancer from men with benign prostatic hyperplasia.

2017-02-10 | GSE67068 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data